Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CEMP's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CEMP Guru Trades in Q1 2016

George Soros 181,825 sh (New)
Jim Simons 30,330 sh (New)
» More
Q2 2016

CEMP Guru Trades in Q2 2016

Jim Simons 205,300 sh (+576.89%)
George Soros Sold Out
» More
Q3 2016

CEMP Guru Trades in Q3 2016

Mario Gabelli 53,400 sh (New)
Jim Simons Sold Out
» More
Q4 2016

CEMP Guru Trades in Q4 2016

Paul Tudor Jones 213,600 sh (New)
Jim Simons 611,200 sh (New)
Mario Gabelli 38,600 sh (-27.72%)
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:MNOV, NAS:ABEO, NAS:CYAD, OTCPK:SPHRY, OTCPK:SPRWF, NAS:CGEN, OTCPK:VNLPY, OTCPK:THERF, OTCPK:OXBDF, NAS:NVLN, NAS:AUPH, NAS:AVXL, NAS:IMGN, OTCPK:ELVAF, NAS:MDGL, OTCPK:BNRPF, OTCPK:SIGA, NAS:MNKD, NAS:IDRA, NAS:VBIV » details
Traded in other countries:9C1.Germany,
Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.

Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $15.87
EPS (TTM) $ -2.22
Beta0.87
Short Percentage of Float16.92%
52-Week Range $2.55 - 26.95
Shares Outstanding (Mil)52.38

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 17 34 57
EPS ($) -2.36 -0.94 -0.74 -0.25
EPS without NRI ($) -2.36 -0.94 -0.74 -0.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
Top Biopharma Movers of the Past Week Feb 25 2017
7:01 am Cempra announces positive topline results from a phase 3 study of oral fusidic acid in 716... Feb 25 2017
Cempra shares up following skin infection trial results, but still a long way from full recovery Feb 24 2017
Is This the Turnaround Cempra Has Been Looking For? Feb 24 2017
Biotech Movers: Cempra Flys High On Phase Three Results Feb 24 2017
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 24 2017
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI Feb 24 2017
Cempra to Report Fourth Quarter and Full Year 2016 Financial Results Feb 14 2017
CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences Feb 08 2017
Cempra to Present at Upcoming Investor Conferences Feb 08 2017
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda... Jan 25 2017
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season? Jan 24 2017
Cempra (CEMP): An Off-the-Radar Potential Winner Jan 23 2017
Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs Jan 11 2017
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 09 2017
Cempra to Present at J.P. Morgan Healthcare Conference Jan 04 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and... Jan 03 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, Inc. of a Class Action Lawsuit... Jan 03 2017
Is the Options Market Predicting a Spike in Cempra (CEMP) Stock? Jan 03 2017
Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session Jan 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)